General Information

We are a leading data-driven diagnostic solutions company leveraging state of the art technologies with our proprietary artificial intelligence (AI) platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. By combining a technology agnostic approach with a holistic view of the patient’s disease state, we believe our solutions provide physicians with greater insights to help personalize their patient’s care and meaningfully improve disease detection, evaluation, and treatment.

We have four diagnostic blood-based tests across the lung cancer continuum of care : Nodify XL2 and Nodify CDT (both trademarked) tests, marketed as part of our Nodify Lung module, to help assess the risk of lung cancer, and GeneStrat and VeriStrat (both trademarked) tests, marketed as part of our Biodesix Lung Reflect testing strategy, used following diagnosis of lung cancer.

In response to the global pandemic, we have commercialized the Biodesix WorkSafe™ COVID-19 Testing Program, which includes two EUA-FDA authorized tests (molecular & serology) for the SARS-CoV-2 virus in partnership with Bio-Rad Laboratories.


Industry: Services - Medical Laboratories
Employees: 154
Founded: 2005
Contact Information
Address 2970 Wilderness Place, Suite 100 Boulder, Colorado 80301
Phone Number (303) 417-0500
Web Address
View Prospectus: Biodesix
Financial Information
Market Cap $475.56mil
Revenues $21.6 mil (last 12 months)
Net Income $-34.1 mil (last 12 months)
IPO Profile
Symbol BDSX
Exchange NASDAQ
Shares (millions): 4.0
Price range $18.00 - $18.00
Est. $ Volume $72.0 mil
Manager / Joint Managers Morgan Stanley/ William Blair
CO-Managers Canaccord Genuity/ BTIG
Expected To Trade: 10/28/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change